Hepatocyte-Specific Casein Kinase 1 Epsilon Ablation Ameliorates Metabolic Dysfunction-Associated Steatohepatitis by

Mwense Leya1, Hyuneui Jeong2, Daram Yang2

  • 1Biosafety Research Institute and College of Veterinary Medicine, Jeonbuk National University, Iksan-si, Republic of Korea; School of Veterinary Medicine, University of Namibia, Windhoek, Namibia.

PubMed

Insights

Casein kinase 1 epsilon (CK1ε) drives metabolic dysfunction-associated steatohepatitis (MASH) by promoting inflammation and lipid metabolism. Inhibiting CK1ε reduces MASH severity, offering a potential therapeutic target for liver disease.

Area of Science:

  • Biochemistry
  • Hepatology
  • Molecular Biology

Background:

  • Chronic liver diseases, including MASH, represent a significant global health burden.
  • The precise molecular mechanisms underlying MASH pathogenesis are not fully understood.
  • Casein kinase 1 epsilon (CK1ε), a serine/threonine kinase, has a poorly defined role in liver disease.

Purpose of the Study:

  • To investigate the role of CK1ε in the development and progression of MASH.
  • To elucidate the molecular pathways influenced by CK1ε in MASH.
  • To evaluate the therapeutic potential of CK1ε inhibition in MASH.

Main Methods:

  • Generation of hepatocyte-specific CK1ε knockout (CK1εΔHEP) mice.
  • Induction of MASH using Western diet (WD) or methionine- and choline-deficient (MCD) diet.
  • Assessment of liver injury, inflammation, lipid metabolism, and key signaling pathways (TNF-α, TRAF3, TBK1, AKT, MAPK).
  • In vitro and in vivo evaluation of the CK1ε inhibitor PF670462.

Main Results:

  • CK1εΔHEP mice exhibited reduced MASH severity, hepatic lesions, and liver enzymes (ALT, AST) in response to WD or MCD diet.
  • CK1ε deficiency ameliorated lipid accumulation (cholesterol, triglycerides) and suppressed lipogenic gene expression in WD-fed mice.
  • CK1εΔHEP mice showed downregulated TRAF3, p-TAK1, p-TBK1, and p-AKT, impacting MAPK signaling.
  • PF670462 treatment improved palmitic acid-induced steatohepatitis in vitro and attenuated WD-induced metabolic dysfunction in vivo.

Conclusions:

  • CK1ε exacerbates MASH by upregulating TRAF3, leading to TAK1-dependent signaling, amplified MAPK activation, and increased inflammation.
  • CK1ε plays a critical role in regulating lipid metabolism and inflammatory responses in the liver.
  • Targeting CK1ε with pharmacologic inhibitors like PF670462 presents a promising therapeutic strategy for MASH.

Related Concept Videos